Opendata, web and dolomites

PERIF SIGNED

Perivascular cells at the crossroads of inflammation, regeneration and fibrosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PERIF project word cloud

Explore the words cloud of the PERIF project. It provides you a very rough idea of what is the project "PERIF" about.

threatening    half    agent    mural    protective    function    fibrous    massive    usually    fibrosis    inflammatory    mesenchymal    discrete    vessels    harmful    liver    avenues    survival    initially    contaminated    last    dystrophies    recovery    collectively    wraps    population    drew    functional    inappropriate    wound    relative    replaces    organ    activation    intend    neutralize    stromal    unexpected    adult    inflammation    host    variously    normal    biological    world    mediators    hindered    tissue    identification    roles    area    damaged    muscular    preventing    mechanisms    injury    partial    regulating    life    diversity    suggests    point    fibrotic    mediated    necrotic    heal    previously    regulation    invaders    fight    cells    scarring    blood    repair    paving    pericytes    diseases    foreign    disease    transiently    vascular    industrialized    data    tumors    functions    birth    immune    scleroderma    perivascular    eliminate    beneficial    cardiovascular    team    injured    questions    scar    excessive    source    profibrotic    cancer    therapeutic    settings    organisms    bowel    tissues    generating    chronic    notable    medicine    regeneration    lung    deaths    nearly    kidney   

Project "PERIF" data sheet

The following table provides information about the project.

Coordinator
INSTITUT PASTEUR 

Organization address
address: RUE DU DOCTEUR ROUX 25-28
city: PARIS CEDEX 15
postcode: 75724
website: http://www.pasteur.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 1˙976˙100 €
 EC max contribution 1˙976˙100 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-CoG
 Funding Scheme ERC-COG
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2021-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT PASTEUR FR (PARIS CEDEX 15) coordinator 1˙976˙100.00

Map

 Project objective

The survival of organisms requires the ability to repair tissues upon injury, as well as, after birth, to fight foreign invaders that may have contaminated the wound. This last function is mediated by a complex host response involving immune cells, blood vessels and inflammatory mediators that collectively intend to neutralize the harmful agent and eliminate damaged/necrotic tissue. Initially beneficial, this massive inflammatory response comes with a cost, and adult injured tissues usually heal with a scar, which is an area of fibrous tissue that transiently replaces normal tissue. In chronic settings, scarring can become excessive in a process called fibrosis, to the point of preventing functional recovery of the injured organ and be life threatening. Nearly half of all deaths in industrialized world are due to diseases involving inappropriate, often chronic, inflammatory and fibrotic responses, including lung, kidney and liver diseases, scleroderma, inflammatory bowel diseases, muscular dystrophies, cardiovascular diseases, and tumors. However our current knowledge of the biological processes regulating fibrosis is partial, which has hindered therapeutic advances in the field. Recent data from our team and others drew new attention on a discrete population of mesenchymal cells that wraps around vessels, variously called mural cells, perivascular cells or pericytes, as a major source for profibrotic stromal cells generating scar tissue. Previously known for their vascular protective functions, increasing evidence suggests new and unexpected roles for these cells also in inflammation, repair/regeneration, and cancer. These new findings raise a number of challenging questions relative to their functional diversity, as well as mechanisms of activation/ regulation in disease. The identification and specific targeting of functional subsets of mesenchymal perivascular cells may have notable impact in research and medicine, paving the way for new therapeutic avenues in inflammatory/fibrotic diseases and cancer.

 Publications

year authors and title journal last update
List of publications.
2018 Selene E. Di Carlo, Lucie Peduto
The perivascular origin of pathological fibroblasts
published pages: 54-63, ISSN: 0021-9738, DOI: 10.1172/JCI93558
Journal of Clinical Investigation 128/1 2019-07-25
2017 Igor Stzepourginski, Giulia Nigro, Jean-Marie Jacob, Sophie Dulauroy, Philippe J. Sansonetti, G?rard Eberl, Lucie Peduto
CD34 + mesenchymal cells are a major component of the intestinal stem cells niche at homeostasis and after injury
published pages: E506-E513, ISSN: 0027-8424, DOI: 10.1073/pnas.1620059114
Proceedings of the National Academy of Sciences 114/4 2019-07-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERIF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERIF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

QUAMAP (2019)

Quasiconformal Methods in Analysis and Applications

Read More  

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More